Combined Hyperglycemia and Hyperinsulinemia-induced Insulin Resistance in Adipocytes is associated with Dual Signaling Defects mediated by PKC-ζ by Lu, Huogen et al.
                                                              
University of Dundee
Combined Hyperglycemia and Hyperinsulinemia-induced Insulin Resistance in
Adipocytes is associated with Dual Signaling Defects mediated by PKC-
Lu, Huogen; Bogdanovic, Elena; Yu, Zhiwen; Cho, Charles; Liu, Lijiang; Ho, Karen; Guo,
June; Yeung, Lucy S. N.; Lehmann, Reiner; Hundal, Harinder S.; Giacca, Adria; Fantus, I.
George
Published in:
Endocrinology
DOI:
10.1210/en.2017-00312
Publication date:
2018
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Lu, H., Bogdanovic, E., Yu, Z., Cho, C., Liu, L., Ho, K., ... Fantus, I. G. (2018). Combined Hyperglycemia and
Hyperinsulinemia-induced Insulin Resistance in Adipocytes is associated with Dual Signaling Defects mediated
by PKC-. Endocrinology, 159(4), 1658-1677. https://doi.org/10.1210/en.2017-00312
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
 Combined Hyperglycemia and Hyperinsulinemia-induced Insulin 
Resistance in Adipocytes is associated with Dual Signaling Defects 
mediated by PKC-ζ 
 
Huogen Lu, Elena Bogdanovic, Zhiwen Yu, Charles Cho, Lijiang Liu, Karen Ho, June 
Guo, Lucy SN Yeung, Reiner Lehmann, Harinder S. Hundal, Adria Giacca and I. George 
Fantus 
 
Endocrinology 
Endocrine Society 
 
Submitted: March 31, 2017 
Accepted: January 03, 2018 
First Online: January 23, 2018 
 
Advance Articles are PDF versions of manuscripts that have been peer reviewed and accepted but 
not yet copyedited. The manuscripts are published online as soon as possible after acceptance and 
before the copyedited, typeset articles are published. They are posted "as is" (i.e., as submitted by 
the authors at the modification stage), and do not reflect editorial changes. No 
corrections/changes to the PDF manuscripts are accepted. Accordingly, there likely will be 
differences between the Advance Article manuscripts and the final, typeset articles. The 
manuscripts remain listed on the Advance Article page until the final, typeset articles are posted. 
At that point, the manuscripts are removed from the Advance Article page. 
 
DISCLAIMER: These manuscripts are provided "as is" without warranty of any kind, either express 
or particular purpose, or non-infringement. Changes will be made to these manuscripts before 
publication. Review and/or use or reliance on these materials is at the discretion and risk of the 
reader/user. In no event shall the Endocrine Society be liable for damages of any kind arising 
references to, products or publications do not imply endorsement of that product or publication. 
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
Downloaded from https://academic.oup.com/endo/advance-article-abstract/doi/10.1210/en.2017-00312/4822182
by Library - Duncan of Jordanstone user
on 31 January 2018
AD
VA
NC
E 
AR
TI
CL
E
Endocrinology; Copyright 2018  DOI: 10.1210/en.2017-00312 
 
 
1
PKC-ζ and Insulin Resistance 
Combined Hyperglycemia and Hyperinsulinemia-induced Insulin Resistance 
in Adipocytes is associated with Dual Signaling Defects mediated by PKC-ζ 
Huogen Lu1,3, Elena Bogdanovic1,2,3, Zhiwen Yu1,3, Charles Cho1,2, Lijiang Liu1,3, Karen Ho1,3, 
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Departments of Medicine1 Mount Sinai Hospital, Department of Physiology2, Banting and Best Diabetes Centre and 
Toronto General Research Institute3, University Health Network, University of Toronto, Toronto, ON., Canada, The 
Department of Internal Medicine IV, Endocrinology, Metabolism, Pathobiochemistry and Clinical Chemistry, 
University Hospital Tuebingen, D-72076 Tuebingen, Germany4 and Division of Molecular Physiology Unit, Faculty 
of Life Sciences, University of Dundee, Dundee DD15EH, United Kingdom5 
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1.     The abbreviations used are:  GLUT, glucose transporter; IRS-1, insulin receptor substrate-1; GSK, 
glycogen synthase kinase; PKB, protein kinase B; PI, phosphatidylinositol; SH2, Src homology 2; PM, 
plasma membrane; LDM, low density microsomes; mTORC2, mammalian target of rapamycin-rictor 
complex 2; PKC, protein kinase C; PS, pseudosubstrate; HG/HG, high glucose/high insulin; 2DG, 2-
deoxyglucose; DMEM, Dulbecco’s modified Eagles medium; FBS, fetal bovine serum; KRBH, Krebs 
Ringer Bicarbonate HEPES; TES, Tris EDTA sucrose; PMSF, phenylmethylsulfonide fluoride; HA, 
hemagglutinin; GFP, green fluorescent protein. 
A hyperglycemic and hyperinsulinemic environment characteristic of type 2 diabetes causes 
insulin resistance.  In adipocytes, defects in both insulin sensitivity and maximum response of 
glucose transport have been demonstrated.  To investigate the molecular mechanisms, freshly 
isolated rat adipocytes were incubated in control (5.6 mM glucose, no insulin) and high glucose 
(20 mM)/high insulin (100 nM) (HG/HI) for 18 h to induce insulin resistance.  Insulin resistant 
adipocytes manifested decreased sensitivity of glucose uptake associated with defects in IRS-1 
Tyr phosphorylation, association of p85 subunit of phosphatidylinositol-3-kinase, AktSer473 and 
Thr308 phosphorylation accompanied by impaired glucose transporter 4 translocation.  In 
contrast, PKC-ζ activity was augmented by chronic HG/HI.  Inhibition of PKC-ζ with a specific 
cell permeable peptide reversed the signalling defects and insulin sensitivity of glucose uptake.  
Transfection of dominant-negative kinase-inactive PKC-ζ blocked insulin resistance, while 
constitutively-active PKC-ζ recapitulated the defects.  The HG/HI incubation was associated 
with stimulation of IRS-1Ser318 and AktThr34 phosphorylation, targets of PKC-ζ.  Transfection 
of IRS-1S318A and AktT34A each partially corrected, while combined transfection of both 
completely normalized insulin signaling. In vivo hyperglycemia/hyperinsulinemia in rats, for 48h 
similarly resulted in activation of PKC-ζ and increased phosphorylation of IRS-1 Ser318 and 
AktThr 34. These data indicate that impairment of insulin signaling by chronic HG/HI is 
mediated by dual defects at IRS-1 and Akt mediated by PKC-ζ. 
Chronic activation of PKC-ζ decreases insulin sensitivity of glucose transport in adipocytes exposed to 
combined hyperglycemia/hyperinsulinemia by phosphorylation of dual targets, IRS-1 and Akt.  
Introduction 
Peripheral resistance to the action of insulin is a key contributor to the development of type 2 
diabetes and is associated with an increased risk of cardiovascular disease (1-3).  Several factors 
contributing to insulin resistance have been identified including increased circulating fuels, 
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glucose, free fatty acids (FFA) and amino acids (3-5).  In the case of glucose, induction of in 
vivo hyperglycemia by partial pancreatectomy or streptozotocin resulted in the development of 
whole body insulin resistance which was corrected by normalization of glucose concentrations 
(6, 7). Rats infused with high glucose for 72 h show impaired insulin-stimulated glucose uptake 
in vivo and in isolated tissues (8).  In an in vitro model, chronic exposure (18 h) of primary 
cultured rat adipocytes to high concentrations of glucose combined with insulin impaired the 
ability of insulin to acutely stimulate glucose uptake (9). In this model two types of defects, 
namely, decreased insulin sensitivity (a shift to the right of the insulin dose-response curve) and 
decreased responsiveness (maximum insulin response), were noted.  The molecular mechanisms 
that account for these changes have not been defined. 
Insulin stimulates glucose entry into skeletal muscle and adipose tissue by promoting the 
translocation of glucose transporters (GLUTs),  mainly GLUT4, from intracellular storage sites 
to the plasma membrane (PM) (10).  Insulin binds to the cell surface insulin receptor, activates 
its intrinsic tyrosine kinase that phosphorylates insulin receptor substrates (IRSs) (reviewed in 
2,11). This results in binding and activation of phosphatidylinositol 3-kinase (PI 3-kinase), which 
catalyzes the formation of 3′phosphorylated lipid products, PI(3,4)P2 and PI (3,4,5)P3. (12).  
These lipids recruit Akt/protein kinase B (PKB) to the PM and activate the enzyme by its 
phosphorylation on Thr308 by phosphoinositide-dependent kinase-1 (PDK-1) and Ser473 by the  
rictor/mTOR complex (mTORC2), respectively (12-14).  Akt activation leads to GLUT4 
translocation and glucose uptake (15,16).  In addition to glucose transport, Akt has been 
implicated in the stimulation of glycogen synthesis, protein synthesis, transcription, and cell 
survival (16,17).   
Atypical protein kinase C-ζ/λ (PKC-ζ) is also activated by insulin in a PI 3-kinase dependent 
manner (18,19). This Ser/Thr kinase has also been implicated in glucose transport stimulated by 
insulin in adipocytes and skeletal muscle (19-22). On the other hand, PKC-ζ has also been found 
to negatively regulate  insulin signaling by phosphorylating IRS-1 (23-26). PKC-ζ has also been 
reported to phosphorylate Akt and inhibit its activation, associated with metabolic conditions 
(27).  However, the role of PKC-ζ and these targets of phosphorylation in the pathogenesis of 
insulin resistance in adipocytes has not been well documented.  The unique challenge of 
investigating PKC-ζ is due to the fact that knockout or inhibition of atypical PKC blocks insulin-
stimulated glucose transport in target tissues, muscle and adipocytes  (20,28). 
In this study we investigated insulin signaling in primary cultured rat adipocytes rendered 
insulin resistant by chronic (18 h) incubation with 20 mM glucose and 100 nM insulin (HG/HI).  
Tyr phosphorylation of IRS-1, its association with the p85 subunit of PI3K and insulin-
stimulated Akt activation were impaired.   Surprisingly, in contrast, PKC-ζ activity remained 
abnormally elevated in the basal state and its inhibition was associated with a recovery of the 
response to insulin.   Concomitant with these findings, impaired GLUT4 translocation and 
decreased sensitivity of glucose transport were normalized by inhibiting PKC-ζ prior to 
restimulation with insulin. Transfection of adipocytes with IRS-1S318A or with Akt T34A, 
mutants of IRS-1 and Akt respectively, in which the Ser/Thr residues recognized as 
phosphorylation targets of PKC-ζ (26,29) were substituted for alanine, partially restored the 
defects induced by cotransfected CA (constitutively active) –PKC-ζ or by HG/HI, while 
cotransfection with both IRS-1S318A and AktT34A completely corrected these defects. 
Furthermore, 48h in vivo combined hyperglycemia/hyperinsulinemia-induced insulin resistance 
was associated with increased IRS-1 Ser318, Akt Thr 34 and PKC-ζ Thr 410 phosphorylation.  
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These data indicate that combined hyperglycemia/hyperinsulinemia-induced insulin resistance is 
due to  enhanced PKC-ζ activity which causes dual defects at the level of IRS-1 and Akt.  
Materials and Methods 
 Reagents:   
Dulbecco’s Modified Eagle’s medium (DMEM), fetal bovine serum (FBS), antibiotics, and the 
PKC-ζ peptide substrate {[Ser25] PKC residues (19-31)} were purchased from Invitrogen. Type 
1 collagenase was from Worthington Biochemicals Corp.  (Freehold, NJ).  The following 
chemicals were obtained from Sigma, bovine serum albumin (BSA fraction V), phthalic acid 
dinonyl ester, rotenone, phloretin, microcystin-RR, 2-deoxyglucose (2DG), and all chemicals 
used for KRBH (Krebs Ringer Bicarbonate HEPES) and KR30H (KR 30 mM HEPES) buffers. 
L-α-phosphatidylinositol and myristoylated PKC-ζ pseudosubstrate  peptide inhibitor (human 
PKCζ (amino acid residues 113-125)) (PS) were obtained from Biomol.  Anti-phosphotyrosine 
(pY) (4G10) conjugated to agarose, Akt1/PKBα Immunoprecipitation and Kinase Assay Kit, 
Akt/PKB substrate peptide Crosstide, antibodies against the p85 subunit of PI3-kinase,IRS-1, 
IRS-1 pSer307, IRS-1 pSer636/639 and agarose-conjugated anti-IRS-1 were obtained from 
Upstate-Millipore.  Anti-pY (PY99), antibodies against PKC-ζ/λ, anti-Akt2/PKB-β,anti-myc and 
anti-PKCs (-β1,-δ and -ε) were from Santa Cruz.  Phospho-specific antibodies against Akt 
pSer473, Akt pThr308, GSK-3α/β pSer21/Ser9, PKC-ζ pThr 410 and antibodies against total 
PKB and PKC-ζ were obtained from Cell Signaling.  Antibodies against GSK3α/β and 
myristoylated PKC-α/β pseudosubstrate peptide inhibitor (PKC-α residues 20-28) were obtained 
from Calbiochem-Millipore Antibodies against GLUT1 and GLUT4 were a kind gift from Dr. S. 
Cushman (National Institutes of Health, Bethesda, MD) or from Novus and Calbiochem-
Millipore respectively.  Antibody against PKB pThr34 was from Abcam Inc. (Cambridge, MA) 
and anti-HA from COVANCE (Denver, PA) (Suppl. Table 1).  2-deoxy-D-[3H] glucose (30 
Ci/mmol) and [γ-32P] ATP (3000 Ci/mmol) were obtained from DuPont-NEN.  Nitrocellulose 
membranes (0.45 µm) for protein transfer were obtained from Schleicher & Schuell (Keene, 
NH). The enhanced chemiluminescence (ECL) reagent was obtained from Amersham.  Human 
insulin was a gift from Eli Lilly (Indianapolis, IN). 
Primary culture of rat adipocytes:   
Male Sprague-Dawley rats (Charles River) weighing 200-250 g were sacrificed by exposure to 
30% O2/70% CO2 followed by 100% CO2 and cervical dislocation. Animal studies were carried 
out in accordance with policies and guidelines of the Canadian Council on Animal Care and 
approved by the University Health Network Animal Care Committee.  The epididymal fat pads 
were removed and adipocytes liberated by collagenase digestion as previously described (30). 
Freshly isolated adipocytes were incubated (10% lipocrit) for 18 h at 37°C in DMEM containing 
25 mM HEPES, 1% penicillin-streptomycin, 0.5% FBS, and 1% BSA. Cells were incubated 
either in media alone (Control, 5.6 mM glucose), or containing 20 mM glucose and 100 nM 
insulin (high glucose (HG)/high insulin (HI), Resistant). All incubations were carried out in a 
humidified atmosphere of 95% air/5% CO2. For inhibition of PKC-ζ activity, cells were treated 
with PS for the final 2 h. Following the 18 h incubation, cells were washed twice with KR30H 
buffer (137 mM NaC1, 5 mM KC1, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1.25 mM CaCl2, 30 mM 
HEPES, 1 mM pyruvate, pH 7.0) containing 3% BSA, and then incubated in the same buffer for 
30 min at 37°C to remove all extracellular and receptor bound insulin (9).  The cells were then 
washed twice in KRBH buffer (118 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.2 
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mM KH2PO4, 5 mM NaHCO3, 30 mM HEPES, 1 mM pyruvate, pH 7.5) containing 3% BSA and 
then re-suspended in the same buffer for subsequent stimulation with insulin. 
2-deoxyglucose uptake assay:   
To assess 2-deoxyglucose (2DG) uptake, adipocytes (6 x 105 cells/ml final concentration) were 
incubated in a shaking water bath for 30 min at 37°C in the presence of various concentrations of 
insulin (0-100 nM) and carried out as described (31). 
Subcellular fractionation of rat adipocytes:   
Cells stimulated with or without insulin were washed once with TES homogenization buffer (25 
mM Tris, pH 7.4, 2 mM EDTA, 0.25 M sucrose, 0.01 mg/ml aprotinin, 0.01 mg/ml leupeptin, 
0.1 mM PMSF) equilibrated at 18°C and homogenized. All subsequent steps were performed at 
4°C as described (31). The PM and LDM (low density microsomes) fractions (pellet) were 
resuspended in Buffer A (50 mM Tris, PH7.5, 1 mM EDTA, 1 mM EGTA, 0.5 mM sodium 
orthovanadate, 0.1% 2-mercaptoethanol, 1% Triton X-100, 50 mM sodium fluoride, 5 mM 
sodium pyrophosphate, 10 mM sodium glycerophosphate, 0.1 mM PMSF, 1 µM microcystin-
RR, 1 µg/ml each of aproptinin, pepstatin, and leupeptin) and stored at –80°C.  The purity of the 
membrane fractions was confirmed by assays of the PM marker, 5’nucleotidase (Sigma) which 
was 12.5-fold enriched in PM compared with LDM.  The purity and protein yields of PM and 
LDM were similar in control and resistant cells (not shown). 
Western blotting:  
Adipocytes were solubilized by adding 300 µl of lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM 
EDTA, 1 mM EGTA, 0.5 mM sodium orthovanadate, 0.1% 2-mercaptoethanol, 1% Triton X-
100, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 10 mM sodium β-glycerophosphate, 
0.1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1µg/ml leupeptin, and 0.1 µg/ml okadaic 
acid) per ml of cells followed by homogenization. After centrifugation, the fat was removed, and 
the infranatant was stored at -70°C. Laemmli sample buffer (3x) with 0.006% bromphenol blue 
was added to equal aliquots of protein (Bradford assay) and boiled for 5 min. For GLUT4 and 
GLUT1, urea sample buffer was used (6.86 mol/l urea, 4.29% SDS, 43 mM Tris-HCl, and 300 
mM dithiothreitol). For immunoprecipitation, 1 mg of whole cell lysates were incubated with 4 
µg of antibody at 4°C overnight followed by addition of 30 µl of protein A/G-agarose beads for 
2 h or for IRS-1, with agarose-conjugated antibody. The samples were centrifuged, washed and 
separated by SDS-PAGE. Proteins were transferred onto nitrocellulose membranes, and 
immunoblotting performed as described (31). Intensities of all phosphoprotein immunoblots 
were corrected for the relevant total proteins in each experiment. 
Enzyme activity assay:   
Cells stimulated with or without insulin were washed twice with ice-cold KRBH and lysed as 
above.  Akt was immunoprecipitated and immunocomplexes washed 3 times with lysis buffer 
containing 0.5 M NaCl, twice with washing buffer (50 mM Tris-HCl, pH 7.5, 0.03% (w/v) Brij-
35, 0.1 mM EGTA and 0.1% 2-mercaptoethanol), and once with the Akt kinase assay buffer (20 
mM MOPS, pH 7.2, 25 mM sodium β-glycerophosphate, 5 mM EGTA, 1 mM sodium 
orthovanadate, 1 mM DTT).  Immunoprecipitates were incubated in the assay buffer containing γ 
[32P]-ATP (10 µCi), and 10 µM Protein Kinase A inhibitor peptide (amino acids 6-22 amide, 
Calbiochem) and 30 µM of the peptide substrate Crosstide for 10 min at 30°C.  The reaction was 
terminated by centrifugation and the supernatants spotted on P81 phosphocellulose paper.  After 
washing 4 times with 0.5% phosphoric acid and once with 95% ethanol, radioactivity was 
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determined by scintillation counting. PKCζ was immunoprecipitated with 2 µg PKCζ/λ antibody 
at 4°C followed by the addition of Protein A/G agarose (30 µl) for an additional 2 h.  The 
immunocomplexes were washed twice with lysis buffer and twice with kinase assay buffer (50 
mM Tris, pH 7.5, 5 mM MgCl2, 0.1 mM Na3VO4, 0.1 mM Na4P2O7, 0.1 mM NaF and 0.1 mM 
PMSF) and activity assayed as described by Standaert (19). 
Measurement of Akt dephosphorylation:   
Akt pSer473 dephosphorylation was determined in living adipocytes in situ and in cell lysates in 
vitro.  Following the 18 h incubation, adipocytes were washed and re-stimulated with 100 nM 
insulin for 15 min at 37°C followed by the addition of 100 µM 2-DG and 5 µM rotenone to 
deplete cellular ATP as previously described (30,32).  The cells were then incubated at either 
37°C or 30°C for various times, rapidly washed, and lysed in buffer containing 250 mM sucrose. 
Cell lysates were subjected to SDS-PAGE and immunoblotted for total and pSer473 Akt as 
above.  To determine dephosphorylation activity in vitro, lysates were prepared from adipocytes 
incubated for 18 h with or without HG/HI.  Phosphorylated Akt immunoprecipitated from 
insulin-stimulated control adipocyte lysates was used as substrate. The immunocomplexes were 
washed twice with lysis buffer and twice with phosphatase assay buffer (100 mM HEPES, pH 
7.5, 150 mM NaCl, 2 mM EDTA, 1 mM EGTA, and 1 mM DTT) and used immediately.  Akt 
dephosphorylation was inititated by adding equal amounts of immunoprecipitated 
phosphorylated Akt protein to 50 µg cell lysates from control and resistant adipocytes and 
incubated in phosphatase buffer at 30°C for the times indicated.  The reaction was stopped by the 
addition of Leammli sample buffer and boiling for 5 min.  The extent of Akt pSer473 was 
assessed by immunoblotting as above. 
Transfection of adipocytes:  
Freshly isolated adipocytes were transiently transfected by electroporation as described 
previously (31,33). Briefly, 0.4 ml of adipocyte suspension (lipocrit of 60%) was added to 0.4-
cm gap-width cuvettes with equal volumes of DMEM containing 7.5 µg of plasmid encoding 
various proteins and electroporated in the Gene Pulser Xcell TM Electroporation System (CE 
Module, Bio-Rad) by two pulses of 25 µF at 800 V followed by one pulse of 1,050 µF at 200V. 
Transfected cells were washed and incubated with DMEM containing 5% BSA for at least 18 h.  
GLUT4 translocation determined by fluorescence microscopy.  
Primary adipocytes were electroprated as described above with pQB125 plasmid encoding 
hemagglutinin-GLUT4-green fluorescent protein (HA-GLUT4-GFP) (S.W.Cushman, NIH, 
Bethesda, MD).  After induction of insulin resistance, washing and restimulation with insulin as 
described above, cells were incubated with anti-GFP and mouse monoclonal anti-hemagglutinin 
antibody (1:150) and donkey anti-mouse IgG antibody conjugated with rhodamine red (1:100), 
fixed in 4% paraformaldehyde in PBS, and mounted on glass slides using Vectashield mounting 
medium as described (31). Fluorescence was observed using the Leica TCS SP2 Confocal Laser 
Scanning Microscope and analyzed with Leica Confocal Software.  The intensities of the red 
fluorescence (cell surface GLUT4) were corrected for the green (total GLUT4) in all 
experiments and extent of translocation relative to control determined. 
In vivo studies:   
Female Wistar rats (Charles River, Quebec) were cannulated as described with the carotid artery 
for sampling and jugular vein for infusion (34).  Rats were allowed at least 3 days of recovery 
before infusions.  All protocols and procedures were approved by the University of Toronto 
Animal Care Committee.  Rats (n=8) were randomized and infused for  48h with either saline 
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NaCl (154 mmol/L) (n=4) or a variable infusion of 37.5% (wt/vol) glucose (n=4) to achieve and 
maintain plasma glucose at 20-22 mmol/L.  This 48h hyperglycemic clamp has been previously 
demonstrated  to result in hyperinsulinemia and insulin resistance (34, 35).  After 48h infusion, 
rats were killed and perirenal adipose tissue obtained.  Adipocytes were isolated as described 
above and stimulated with and without 10-7M insulin for 30 min.  Cell lysis, homogenization and 
immunoblotting were performed as described above. 
Data Analysis:   
Results are expressed as mean ± SE.  Differences were compared by ANOVA followed by the 
Bonferroni multiple comparisons test. Values of p<0.05 were accepted as significant.  Paired t-
tests were performed for values of glucose uptake at different insulin concentrations (Fig.1A) 
and dephosphorylation assays at different time points (Fig.3).  For insulin-stimulated glucose 
uptake, the concentrations of insulin required for half maximal stimulation, EC50, were 
determined from dose-response curves using nonlinear regression sigmoidal (four-parameter 
logistic) curve fitting, and signifcant differences were determined using the F test (Graph 
PadPrism Version 4.0, Graph Pad Software, San Diego, CA). 
Results 
High glucose/insulin impairs glucose uptake and GLUT4 translocation:   
When the responses of rat adipocytes to acute insulin stimulation were examined after incubation 
for 18 h in the presence of high glucose/insulin (20 mM glucose/100 nM insulin), the cells 
showed a consistent and marked decrease in 2-DG uptake at all concentrations of insulin 
(Fig.1A).  At the maximum insulin concentration tested, glucose uptake was significantly lower 
in resistant cells (control 816±156 pmol/6x105 cells/3 min, resistant 326±27, p<0.05).  
Adipocytes treated with high glucose/insulin also showed a marked decrease in basal glucose 
uptake (control 240±71 pmol/6x105 cells/3 min, resistant 55±11, p<0.001) (Fig.1A). 
Insulin stimulated glucose uptake in fat cells is mediated by GLUT4 which translocates from 
intracellular LDM (low density microsomes) to PM  in response to insulin (10). In control cells 
under basal conditions, virtually all of the GLUT4 (96.4 ± 1%) was found in the LDM. Upon 
insulin stimulation the GLUT4 content in the LDM fraction was reduced to 25.9 ±6% while the 
PM GLUT4 content increased from 3.6 ± 1% to 74.1 ± 6%.  Resistant cells showed a marked 
defect in GLUT4 translocation as the decrease in LDM GLUT4 and increase in PM GLUT4 after 
insulin stimulation were both lower (94.6 ± 2% in LDM basal; 5.3 ±2% in PM basal; 64.3 ± 6% 
in LDM insulin-stimulated, 35.7 ± 6% in PM insulin-stimulated, p<0.05 compared to control) 
(Fig.1B).  In addition to GLUT4, rat adipocytes also contain GLUT1, a ubiquitously expressed 
glucose transporter thought to be responsible for basal glucose uptake (10).  GLUT1 was found 
exclusively in the PM fraction and there was no significant increase upon insulin stimulation in 
either control or resistant cells (Fig.1C).  In adipocytes treated with high glucose/insulin there 
was a marked decrease in GLUT1 content to 20 ± 10% of control (p<0.05), which likely 
accounts for the decrease in basal glucose uptake observed (Fig.1C). 
High glucose/insulin impairs IRS-1 Tyr phosphorylation and downstream signalling:   
To determine the site of the defect in the insulin signalling of GLUT4 translocation in the 
resistant cells, we examined insulin-stimulated Tyr phosphorylation of IRS-1, a substrate of the 
insulin receptor.  High glucose/insulin treatment decreased IRS-1 Tyr phosphorylation in 
response to insulin compared to control cells (control basal 28 ± 6 %, control insulin, designated 
as 100%, resistant basal 27 ± 5 %, resistant insulin 57 ± 9 %; p<0.05, insulin-stimulated control 
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vs resistant; n=3) (Fig.2A). Although in some studies hyperinsulinemia has been reported to 
decrease total levels of IRS-1 by enhancing its degradation (36), under these conditions in 
primary adipocytes, we found no significant change in total IRS-1. 
 Activation of PI 3-kinase and Akt is necessary for GLUT4 translocation and glucose uptake 
(2,12,16). Consistent with the decrease in IRS-1 Tyr phosphorylation, high glucose/insulin 
treatment significantly decreased insulin-stimulated Akt Ser473 phosphorylation to 28.7 ± 5.1 % 
of control, (p<0.05) and Thr308 phosphorylation to 33.7 ± 8.2 % of control (p<0.05) (Fig.2B). 
Total levels of Akt were unchanged by high glucose/insulin treatment.   
Phosphorylation of Akt at Ser473 and Thr308 correlates with enzyme activity.  Indeed, 
insulin-stimulated activation of Akt was impaired by ~50% in high glucose/insulin treated cells 
compared to control cells (14.3 ± 2.8-fold over basal in control adipocytes and 7.8 ± 0.95-fold in 
resistant cells, p<0.05). Basal values did not differ (control designated as 1.0, resistant 0.91 ± 
0.22) (Fig.2C).  To confirm that endogenous in vivo Akt activity was decreased, we determined 
phosphorylation of GSK-3α/β. Insulin increased phosphorylation of GSK-3α/β in control 
adipocytes 4-fold which was decreased by ~30% in the resistant cells (control basal 24.9±9.9%, 
control insulin designated as 100%, resistant basal 23.2±11%, resistant insulin 70.4±6.7%, 
p<0.05 compared with control insulin). There was no change in total GSK-3α/β (Fig. 2B). 
In adipose tissue insulin stimulates the Ser phosphorylation and activation of both 
Akt1/PKBα and Akt2/PKBβ isoforms (16, 17).  However, experiments in knockout mice (37) 
and cultured cells (38) indicate that Akt2/PKBβ is primarily, if not entirely, responsible for 
signalling to glucose transport.  Immunoprecipitation of Akt2/PKBβ from cell lysates with 
isoform-specific antibodies and immunoblotting with anti-pSer473 Akt (recognizes pSer474 
Akt2/PKBβ) revealed that the high glucose/insulin induced defect applied to Akt2/PKBβ 
(Fig.2D). 
It has been suggested that different defects in this model may depend more on the high 
glucose versus insulin (9).  To determine which was predominant for Akt, adipocytes were 
incubated for 18 h in control medium, high glucose (20 mM) without insulin, high insulin (10-
7M) in the absence of glucose in medium supplemented with 1 mM pyruvate, or with combined 
HG/HI.  While insulin alone induced the defect in Akt phosphorylation similar to that observed 
with combined glucose plus insulin, high glucose alone had no effect (Fig. 2E).   
High glucose/insulin does not enhance Akt dephosphorylation:   
Decreased AktSer473 phosphorylation could be due to impaired phosphorylation by an upstream 
kinase or increased dephosphorylation due to increased phosphatase activity. The latter has been 
previously reported in response to palmitate-induced insulin resistance (39).  Thus, the rate of 
Akt pSer473 dephosphorylation was examined.  In vitro, dephosphorylation was assayed by 
incubating immunoprecipitated pSer473 Akt from insulin-stimulated control adipocytes together 
with cell lysates from either control or high glucose/insulin treated adipocytes.  Akt pSer473 was 
dephosphorylated at similar rates (Fig.3A). Since phosphatase activity may have been lost or 
altered by cell disruption, Akt dephosphorylation was measured in situ in intact cells.  Cellular 
ATP was depleted by 90 – 95% within 5 min of addition of rotenone and 2-DG (not shown) 
thereby inhibiting kinase activity.  At 37°C Akt dephosphorylation was rapid, with 70% of 
pSer473 dephosphorylated within 2 min and there was no difference in the rate of 
dephosphorylation in resistant adipocytes compared to control (Fig.3B).  At 30°C the overall rate 
of pSer473 dephosphorylation was slower and at 2 min, Akt Ser473 phosphorylation remained 
significantly higher in high glucose/insulin (HG/HI) treated cells suggesting a slightly decreased 
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phosphatase activity in insulin resistant cells (Fig.3C).  However, this trend was not significant 
taking into account the entire time course.  These findings indicate that the decreased 
phosphorylation of Akt Ser473 in response to insulin in the insulin resistant adipocytes was not 
due to accelerated dephosphorylation. 
High glucose/insulin treatment is associated with chronic activation of PCK-ζ:   
High glucose has been shown to activate various isoforms of PKC in multiple tissues (40, 41),  
most commonly PKC-β and δ. The latter are stimulated by DAG (diacylglycerol), which is 
increased in response to elevated glucose.  In cultured fibroblasts, PKC activation by exposure to 
high glucose has been implicated in the induction of insulin resistance (42).  To test for PKC 
isoform activation in adipocytes, the cells were homogenized and separated into membrane and 
cytosolic fractions and translocation from cytosol to membrane, considered evidence of 
activation, was determined.  While there were no significant changes in PKC-β1/2, PKC-δ, or 
PKC-ε membrane protein content, a significant translocation of PKC-ζ, an atypical PKC, was 
observed in resistant compared to control cells (p<0.01) (Fig.4A). Activation of PKC-ζ, a 
Ser/Thr kinase, is associated with phosphorylation of its kinase loop by PDK-1 (18, 43).  Since 
phosphorylation of the PDK-1 site on Akt, namely Thr308, was decreased in the HG/HI treated 
cells (Fig. 2B), we determined whether PKC-ζ activation by insulin was impaired.  In control 
cells, insulin increased PKC-ζ activity by 184± 31.4% compared to basal (p<0.05) (Fig. 4B). In 
contrast, in HG/HI treated cells PKC-ζ was already activated in the basal state despite the 
removal of the HG/HI medium by the washing procedure. Thus, basal PKC-ζ activity in the 
resistant cells was elevated to a similar extent as the insulin-stimulated controls (238±28.7% of 
control basal, p<0.005) and there was no significant increase in activity upon restimulation with 
insulin (resistant insulin 254± 54.2% of control basal) (Fig. 4B).  
The defect in Akt Ser473 phosphorylation is reversed by inhibition of PKC-ζ:   
Although PKC-ζ has been shown to have a positive role in the insulin stimulation of glucose 
transport, it has also been reported to inhibit insulin action at the level of IRS-1 (23, 24, 26).  In 
addition, in non-insulin target cells, PKC-ζ has been reported to interact with and inhibit Akt (27, 
29).  To investigate whether PKC-ζ could have a role in downregulating Akt activation in this 
model of insulin resistance, adipocytes were cotransfected with expression vectors encoding 
wild-type (WT) myc-Akt (Akt 1)and DN PKC-ζ (rat PKC-ζ 2-592 K281R, J.W. Soh, Columbia 
University, NY) (44). It has been previously demonstrated that upon electroporation, the same 
population of cells takes up both vectors and expresses the proteins (33).  We first confirmed that 
expressed WT myc-Akt manifested the identical defect in insulin-stimulated Ser473 (Fig.5A) 
and Thr308 (not shown) phosphorylation in the high glucose/insulin model.  Cotransfection of 
DN PKC-ζ in control cells resulted in a small (≤ 10%), but consistent, decrease in Ser473 
phosphorylation.  However, in resistant cells, the defect in insulin-stimulated Ser473 
phosphorylation of myc-Akt was reversed (control + pcDNA3
 
designated as 100%, control + 
DN-PKC-ζ 92.2%, resistant + pcDNA 64.7%, resistant + DN PKC-ζ 89.2%) (Fig. 5A). It should 
be noted that the transfected myc-tagged Akt is visible slightly above the endogenous Akt in the 
immunoblots. Considering a transfection efficiency of between 30 – 50%, (documented in 
preliminary experiments with a GFP expressing vector and with HA-GLUT4-GFP, and by 
immunoblotting of total PKC-ζ), we noted that in experiments in which DN PKC-ζ reversed the 
defect, there was an ~4.5-fold overexpression compared to endogenous PKC-ζ (n=4), while in 
those without reversal, expression of DN-PKC-ζ was < 1.5-fold (n=4) indicating the requirement 
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of an increased ratio of DN-mutant to WT to achieve suppression of PKCζ activity. A second 
caveat of these experiments was that if PKC-ζ inhibition by the DN mutant occurred early, the 
reversal could have been due, at least in part, to an inhibition of glucose uptake. This was not 
likely since the Akt defect could be induced by high insulin even in the absence of glucose (Fig. 
2E).   
In contrast to transfection with DN-PKC-ζ, overexpression of constitutively active 
membrane-targeted, myristoylated CA-PKC-ζ (provided by Alex Toker, 18) resulted in 
inhibition of insulin-stimulated Ser473 phosphorylation of the coexpressed myc-Akt, similar to 
the defect caused by high glucose/insulin, and enhanced the high glucose/insulin effect (Fig. 5B).  
Previous observations that overexpression of PKC-ζ could increase glucose uptake independent 
of insulin (19-22) raised the possibility that this effect on Akt phosphorylation could be indirect; 
that is, mediated entirely by enhanced glucose uptake in the transfected population of cells, or 
that PKC-ζ was not sufficient by itself to induce the defect. To eliminate the potential effect of 
glucose uptake, adipocytes were cotransfected as above and incubated in glucose and insulin free 
medium supplemented with 1 mM pyruvate. CA-PKC-ζ inhibited insulin-stimulation of Ser473 
phosphorylation of coexpressed myc-Akt determined in anti-myc immunoprecipitates (Fig. 5C). 
To examine endogenous proteins and other signaling components, we applied a cell 
permeable myristoylated PKC-ζ specific pseudosubstrate inhibitor (PS). High glucose/insulin 
treatment markedly impaired insulin-stimulated IRS-1 Tyr phosphorylation and association of 
the p85 subunit of PI3-kinase, Akt Ser473 and Thr308 and GSK3α/β phosphorylation (Fig.6A).  
Since inhibition of PKC-ζ has been reported to block insulin-stimulated glucose uptake, and 
indeed, we confirmed that a 30 min preincubation with the PS inhibitor blocked both insulin-
stimulated glucose uptake and PKC-ζ activation (not shown), it was not desirable to add the PS 
inhibitor from the start of the incubation prior to the induction of the insulin resistance.  
However, insulin resistance in this model is well established after 8 h of incubation (9 and data 
not shown). Addition of the PKC-ζ PS inhibitor for only the final 2 h (16-18 h) reversed the 
impairment of IRS-1 Tyr phosphorylation and the association of the p85. PS treatment also 
markedly improved impaired Akt Ser473 and Thr308 phosphorylation observed in resistant cells 
and normalized insulin-stimulated GSK3 phosphorylation (Fig. 6A). To demonstrate specificity 
of the PKC-ζ PS inhibitor, in separate experiments the resistant cells were treated for the final 2 
h with 10 µmol/L of a cell permeable PKC-α/β specific pseudosubstrate inhibitor (N-
myristoylated PKC-α/β amino acid residues 20-28, Calbiochem-Millipore).  There was no rescue 
of the AktSer473 phosphorylation defect with the PKC-α/β PS inhibitor (Fig. 6B).  It should be 
noted that high insulin and high glucose are not required to maintain the insulin resistance during 
this 2 h incubation as washing the cells and reincubating in control medium for the 2 h did not 
reverse insulin resistance (Suppl. Fig. 1). 
Inhibition of PKC-ζ restores insulin sensitivity of glucose uptake:   
To test whether the Akt defect contributed to the decrease in glucose transport, the resistant 
adipocytes were exposed to the PKC-ζ PS inhibitor for the final 2 h as described above.  It was 
first determined that treatment of control adipocytes for 2 h with the PKC-ζ inhibitor, followed 
by the washing procedure allowed for full recovery of glucose uptake (not shown). Reversal of 
the Akt phosphorylation defect with the PKC-ζ PS inhibitor was associated with a restoration of 
relative GLUT4 translocation from LDM to PM seen at maximum insulin concentrations (Fig. 
7A). Similarly, assessment of GLUT4 translocation with HA-tagged GLUT4-GFP using 
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10 
confocal microscopy revealed that the defect induced by exposure to high glucose/insulin was 
reversed by the PKC-ζ PS inhibitor (Fig. 7B).   
Assessment of 2DG uptake revealed that insulin sensitivity was normalized by the PKC-ζ PS 
inhibitor (Fig. 7C and Suppl Fig 2A).  The concentration of insulin required to stimulate 2-DG 
uptake by 50%, EC50, was increased in resistant cells (control 8.8 pmol/L, 95% confidence 
interval (CI) 5.2-14.5; resistant 27.0 pmol/L, 95% CI 15-49, p<0.0001).  After treatment with the 
PKC-ζ PS inhibitor the EC50 in control adipocytes was 4.8 pmol/L, CI 2.9-8.1, and in resistant 
cells was restored to control (9.3 pmol/L, CI 6.2-13.8) (Fig. 7C).  Similar to the results with Akt 
Ser473 phosphorylation, the PKC α/β specific PS inhibitor did not alter the defect in glucose 
uptake induced by HG/HI (Suppl. Fig. 2B).  It should be noted that downregulation of insulin 
receptors (IRs) by high concentrations of insulin has been reported in a number of cell types and 
could have contributed to decreased insulin sensitivity (1-3).  However, we observed only a 
minor and inconsistent decrease (0 – 15%) in cell surface IRs under these conditions and no 
change in total cellular IRs or Tyr phosphorylation of the IR β-subunit as would be expected 
with downregulation (Suppl Fig. 3A).  The maximum response to insulin was also  decreased in 
resistant cells and significantly improved in the presence of the PKC-ζ inhibitor (Fig. 7D).  
While the difference between maximum insulin-stimulated glucose uptake in resistant cells 
treated with PSI and control cells did not reach statistical significance (p=0.08), we noted that it 
remained consistently lower.  It has been shown that even with a significant reduction in Akt 
activation in the order of 75-80%, a high concentration of insulin is able to stimulate maximum 
glucose transport (45).  These data suggest that an additional defect is present that accounts for 
the decrease in maximum insulin response.  Consistent with this interpretation, we observed that 
total GLUT4 content was significantly decreased under these conditions (Suppl. Fig. 3B). 
IRS-1 Ser318 phosphorylation is involved in insulin resistance:   
It has been demonstrated that insulin resistance may be caused by Ser phosphorylation of IRS-1 
(11,25). Phosphorylation of IRS-1 Ser318 has been demonstrated to be mediated by PKC-ζ and 
associated with negative regulation of insulin signaling in BHK and cultured muscle cells (26, 
46). We examined this possibility by cotransfecting cells with CA-PKC-ζ and either wild-type or 
mutant IRS-1 S318A, previously described (46).  We first confirmed that IRS-1 Ser318 was 
phosphorylated in response to insulin and blocked by the PKC-ζ PS inhibitor (Suppl. Fig. 4A). 
Overexpression of CA-PKC-ζ decreased insulin-stimulated Tyr phosphorylation of IRS-1 and 
Akt Ser473 phosphorylation in WT-Akt and WT–IRS-1 cotransfected cells (Fig. 5B and Fig. 
8A). These effects were partially prevented in cells cotransfected with IRS-1 S318A (Fig.  8A). 
Importantly, the defect in IRS-1 Tyr phosphorylation and Akt Ser473 and Thr308 
phosphorylation induced by HG/HI was also diminished in adipocytes cotransfected with IRS-1 
S318A (Fig. 8B). We noted that similar results for IRS-1 Tyr phosphorylation were obtained in 
these transfection experiments in immunoblots of total cell lysates or IRS-1 immunoprecipitates.  
The high degree of correction of the defect in Tyr phosphorylation with IRS-1 S318A to 69 ± 
6.3% of control with CA-PKC-ζ and 88 ± 4.3% with HG/HI may be accounted for by the high 
efficiency of transfection combined with overexpression so that transfected IRS-1 (WT or 
mutant) was in the order of 70 – 80% of total immunoprecipitated IRS-1.  These results indicate 
that the HG/HI induced model of insulin resistance in rat adipocytes is due, in part, to 
phosphorylation of Ser318 of IRS-1 mediated by enhanced activation of PKC-ζ.   
Akt Thr34 phosphorylation by PKC-ζ is involved in insulin resistance:  
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PKC-ζ has been reported to physically interact with Akt leading to phosphorylation of the Akt-
PH domain on Thr34 and preventing activation of the enzyme by insulin (27, 29). We confirmed 
that Akt Thr34 phosphorylation was enhanced by chronic incubation in the high glucose/insulin 
medium and blocked by the PKC-ζ PS inhibitor (Suppl. Fig. 4B). Cotransfection of rat 
adipocytes with CA-PKC-ζ and WT myc-Akt or HA-Akt T34A (described in 29) showed that 
the CA-PKC-ζ-induced decrease in insulin-stimulated Akt Ser473 and Thr308 phosphorylation 
was significantly less with the mutant Akt T34A (Fig.  8C). Transfection of adipocytes with HA-
Akt T34A also partially restored the diminished insulin-stimulated Akt Ser473/Thr308 
phosphorylation induced by HG/HI (Fig. 8D). Significantly, the HG/HI-induced defect in 
Ser473/Thr308 phosphorylation was completely recovered by cotransfection of adipocytes with 
both IRS-1 S318A and Akt T34A (Fig. 8E).  
In vivo hyperglycemia-induced insulin resistance is associated with increased IRS-1 Ser318 and Akt 
Thr34 phosphorylation:   
We previously demonstrated that 48h infusion of glucose to maintain concentrations of 20-22 
mM induces hyperinsulinemia and insulin resistance (34,35).  Thus, rat adipocytes were isolated 
at the end of 48h infusion of saline or glucose and cells stimulated or not with insulin.  
Immunoblotting revealed insulin resistance in adipocytes from glucose-infused rats with defects 
in Akt Ser473 and IRS-1 Tyr phosphorylation (Fig. 9A,B).  This was associated with an 
augmented phosphorylation of Akt Thr34 and IRS-1 Ser318 in the resistant cells (Fig. 9).  In 
contrast, IRS-1 Ser307 phosphorylation was not increased (Fig.9B).  This was consistent with 
our observations in the in vitro studies which did not show any increase in phosphorylation of 
IRS-1 Ser307 or IRS-1 Ser636/639 in the insulin resistant state (Suppl Fig. 5).  Furthermore, the 
high glucose infusion resulted in enhanced phosphorylation of PKC-ζ Thr410, the PDK-1 site 
and a marker of its activation (Fig. 9C).  These in vivo data support the cultured adipocyte 
studies and indicate that PKC-ζ mediates HG/HI-induced insulin resistance via phosphorylation 
of IRS-1 Ser318 and Akt Thr34. 
Discussion 
Both hyperglycemia and hyperinsulinemia have been demonstrated to cause insulin resistance in 
all three metabolic target tissues, fat, muscle and liver (2,3, 47).  In adipocytes this has been most 
clearly demonstrated in primary culture of rat adipocytes exposed to increasing concentrations of 
glucose in combination with insulin (9, 47).  In this model, a decrease in insulin sensitivity, i.e. a 
rightward shift in the dose-response curve of glucose uptake and a decrease in maximum 
response to insulin, as well as a decrease in basal glucose uptake were all observed.  The defect 
in insulin-stimulated glucose uptake was associated with a defect in the movement of GLUT4 
from an internal membrane compartment, LDM, to the PM (Fig.1).  On the other hand, the 
decrease in basal glucose uptake was associated with a marked decrease in PM GLUT1 content.  
In the context of this change in basal glucose uptake and GLUT1, the assessment of insulin 
resistance may be underestimated by the commonly used expression of the increase in glucose 
uptake as fold of basal.  Since the extent of insulin stimulation is accounted for by translocation 
and potential activation of GLUT4, the absolute change in glucose uptake caused by insulin is, in 
this case, a more accurate reflection of insulin action. 
The signaling of GLUT4 translocation and glucose uptake by insulin, although not 
completely understood, requires Tyr phosphorylation of IRS-1 by the insulin receptor and the 
subsequent binding and activation of PI3-kinase.  Lipid phosphorylation results in activation of 
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Akt and PKC-ζ, both implicated in mediating GLUT4 translocation.  In this study, insulin-
stimulated IRS-1 Tyr phosphorylation, IRS-1 association with p85 and activation of Akt were 
significantly decreased in adipocytes chronically exposed to HG/HI. In a similar model, others 
have reported that decreased insulin sensitivity in adipocytes exposed to HG/HI was associated 
with a decrease in total IRS-1 protein (48). In contrast, we did not find a significant change in 
IRS-1 protein content in the resistant adipocytes. Similarly, HG/HI induced insulin resistance 
preceded IRS-1 protein depletion in human adipocytes (49).  In one study in which primary 
adipocytes were cultured in 10% FCS and the duration of exposure was longer, 24 h, high 
glucose alone induced insulin resistance (48). However, we (Fig. 2E) and others (47) did not 
observe this in 0.5% FBS, suggesting that serum factors are required.   
The mechanism of Akt activation entails its recruitment to the PM and phosphorylation on 
two sites, Thr308 and Ser473 by two separate enzymes, PDK-1 and the mTOR/rictor complex, 
respectively (3, 12-14). In this study the high glucose/insulin-induced impaired Akt activation 
was associated with a marked decrease in both Thr308 and Ser473 phosphorylation.  The 
reduction of Akt phosphorylation could have been due to decreased kinase activity or an increase 
in dephosphorylation.  Elevated phosphatase activity of a PP2A family enzyme has been 
implicated in the Akt defect induced by the FFA, palmitate (39).  In contrast, in this HG/HI 
model, we found no change in the rate of Akt pSer473 dephosphorylation. The cause and 
significance of the minimally decreased Akt dephosphorylation in the insulin resistant adipocytes 
at 30°C is not clear. 
As phosphorylation of Akt Thr308 by PDK-1 in the resistant cells was impaired, we assayed 
another downstream target of PDK-1, namely PKC-ζ. Unexpectedly, we found that PKC-ζ 
activity was elevated in the basal state in the resistant cells and not further stimulated by insulin.  
This persistent activation, in spite of extensive washing to remove the HG/HI, was unique in that 
all other parameters examined, including IRS-1 Tyr phosphorylation, association of p85 subunit 
of PI3-kinase, Akt Thr308 and Ser473 phosphorylation and glucose transport, returned to basal 
levels under similar conditions.  The absence of persistent basal Akt Thr308 phosphorylation in 
the resistant cells suggests that PDK-1 may  not be responsible for the elevated PKC-ζ activity. 
PDK-1-independent activation of PKC isoforms, including PKC-ζ, has been reported, but the 
mechanism is not well understood (50). It is also possible that PDK-1 retains some activity and 
that lack of membrane translocation of Akt prevents its Thr308 phosphorylation.  This could be 
explained by the observed Akt Thr34 phosphorylation (29).   
Elevated PKC-ζ activity has also been observed in skeletal muscle in the in vivo 
pathophysiological setting of high fat diet-induced insulin resistance (51). PKC-ζ has been 
reported to negatively regulate insulin action in hepatocytes (23) and adipocytes (24) by 
promoting Ser phosphorylation of IRS-1, associated with decreased insulin-stimulated IRS-1 Tyr 
phosphorylation and activation of PI 3-kinase. Furthermore, exposure of pancreatic β-cells to 
elevated FFAs resulted in chronic activation of PKC-ζ which was associated with impaired IGF-
1 activation of Akt (52).  Together, these findings suggest that PKC-ζ may function as a negative 
feedback regulator.  To probe the role of PKC-ζ in the HG/HI-induced insulin resistant 
adipocytes, we used genetic and pharmacological approaches. Cotransfection of DN PKC-ζ with 
WT-Akt was able to abrogate the induction of the impairment in Akt Ser473 phosphorylation in 
the presence of HG/HI.  However, two caveats of this experiment were considered.  First, a high 
degree of PKC-ζ overexpression was required for the dominant negative action. Second, 
impairment of glucose uptake by PKC-ζ inhibition could have contributed.  Thus, we utilized a 
cell permeable PKC-ζ PS inhibitor peptide.  Incubation with the PKC-ζ inhibitor during  the 
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final 2 h of the HG/HI treatment reversed the Akt defect while simple removal of the HG/HI 
medium for 2 h, or addition of a PKC-α/β PS inhibitor, did not.  While other PKC isoforms have 
been implicated in mediating insulin resistance (reviewed in 2) the lack of effect of the PKCα/β  
inhibitor combined with minimal, nonsignificant membrane increases of these other isoforms 
suggest that in the HG/HI model PKC-ζ is the major mediator.  The observed increase in vivo in 
PKC-ζ phosphorylation of its PDK-1 activation-loop site supports this conclusion.   
To prove the requirement and sufficiency of chronic PKC-ζ activation to induce this defect, 
the adipocytes were cotransfected with expression vectors for CA-PKC-ζ and myc-WT-Akt and 
incubated in medium without glucose and insulin to avoid enhanced glucose uptake in the 
transfected cells.  CA-PKC-ζ was able to recapitulate the defect in Akt Ser473 phosphorylation. 
These results indicate that the elevated PKC-ζ activity is responsible for the defect in Akt 
phosphorylation induced by HG/HI. 
IRS-1 Ser/Thr phosphorylation is a major mechanism leading to insulin resistance and 
several specific phosphorylation sites and kinases have been identified (reviewed in 2). One of 
these sites, Ser318 of IRS-1, has been demonstrated to be a target of PKC-ζ, and its 
phosphorylation was stimulated in BHK cells by 60 min of insulin treatment and associated with 
decreased IRS-1 Tyr phosphorylation and reduced complex formation between IR and IRS-
1(26).  In the present study, the defects in IRS-1 Tyr phosphorylation induced by either CA-
PKC-ζ transfection or by HG/HI treatment were corrected in cells transfected with IRS-1 S318A. 
Of interest, a study in skeletal muscle cells found that, in contrast to prolonged stimulation, acute 
insulin stimulation of IRS-1 Ser318 phosphorylation was not inhibitory, but rather enhanced 
insulin signal transduction (46). This potential sequentially different function of one 
phosphorylation site suggests the possibility that other Ser/Thr sites and/or other kinases may be 
required in addition to IRS-1 Ser318 to mediate the insulin resistance.  A previous study in 
C2C12 cultured muscle cells reported that IRS-1 Ser318 phosphorylation was associated with 
activation of JNK and the PI3K/mTOR pathway (53).  JNK, mTOR and the p70S6K Ser/Thr 
kinases have been documented to cause insulin resistance associated with IRS-1 phosphorylation 
(3).  While we have documented a short term (30-60 min) stimulation of JNK and 
phosphorylation of IRS-1 Ser307, a major target site of JNK, by insulin in adipocytes (31), this 
was not detected at 18 h in vitro (Suppl. Fig. 5) or in vivo (Fig. 9B).  Furthermore, IRS-1 Ser636, 
a target of phosphorylation by the mTOR pathway was not elevated (Suppl. Fig. 5).  One other 
kinase implicated in insulin resistance and downstream of PKC-ζ is IKKβ (2, 54).  However, the 
major target site of IKKβ is also Ser307, which was not phosphorylated under these conditions in 
vitro or in vivo.  In addition, in our previous study we did not detect insulin-stimulated IKKβ 
activation in these primary adipocyte cultures (31).  Together these data indicate that these 
kinases, i.e. JNK, TOR/p70S6K, IKKβ, are not responsible for the maintenance of insulin 
resistance in this longer term HG/HI model.  It should be noted that PKC-ζ has been suggested to 
target other IRS-1 Ser sites, i.e. Ser612, Ser498 and Ser570 (numbering of rat IRS-1, 53), of 
which Ser570 appeared to be key to the induction of insulin resistance (55).  Furthermore, a 
number of other Ser sites, e.g. Ser408, are phosphorylated in response to insulin which may be 
targeted by PKC-ζ (23, 25).  Whether PKC-ζ IRS-1 phosphorylation sites other than Ser 318 
contribute to the insulin resistance in this model requires further investigation.  
Although the transfection of adipocytes with IRS-1 S318A restored IRS-1 Tyr 
phosphorylation by insulin, Akt phosphorylation in these transfected cells was only partly 
recovered. It has been reported that PKC-ζ directly interacts with and represses the activity of 
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Akt (27, 29) and dissociates from Akt upon growth factor and insulin stimulation, thereby 
allowing Akt to become activated. Recent studies showed that in L6 cells, ceramide-activated 
PKC-ζ physically interacts with Akt and phosphorylates the Akt–PH domain on Thr34, leading 
to the inhibition of Akt binding to PI-3,4,5P3 and inhibition of kinase activation by insulin (29). 
In this study, we observed that adipocytes incubated with HG/HI, Akt Thr34 phosphorylation 
was significantly increased in vitro (Suppl. Fig. 4) and in vivo (Fig. 9 ).  Transfection of 
adipocytes with mutant Akt T34A partially restored the impaired Akt Ser473 and Thr308 
phosphorylation induced by either cotransfected CA-PKC-ζ or HG/HI treatment. Thus, PKC-ζ 
causes insulin resistance in this model by at least two mechanisms, targeting IRS-1 as well as 
Akt directly.  Indeed, cotransfection of WT Akt with  a combination of both mutants, IRS-1 
S318A and Akt T34A, completely prevented the defect in Akt phosphorylation induced by 
HG/HI incubation.  This is the first study documenting that chronic HG/HI-induced insulin 
resistance, a metabolic model of early type 2 diabetes, in a physiological target tissue is mediated 
by simultaneous dual targeting of signaling proteins by PKC-ζ. 
At the same time, we noted that a defect in maximum insulin response of glucose transport 
was sustained even in the face of complete restoration of signaling to Akt (Fig.7D) and the 
normalization of the shift in the insulin dose-response curve.  This appears to be due to a 
decrease in total cellular GLUT4 content (Suppl. Fig. 3B) so that fewer absolute numbers of 
transporters are recruited despite a normal relative translocation.  This decrease in GLUT4 
content was induced by insulin and enhanced by high glucose (Suppl. Fig. 3B). The mechanism 
of this second defect remains to be elucidated. 
In summary, this study demonstrates for the first time that PKC-ζ plays a key role as a 
mediator of chronic insulin resistance in a metabolic pathophysiologic state in adipocytes in vitro 
and in vivo.  Furthermore, in this hyperinsulinemia/hyperglycemia model, we demonstrate the 
simultaneous dual targeting of IRS-1 and Akt.   
This chronic negative feedback loop has been challenging to address in the context of 
glucose uptake due to the fact that PKC-ζ also participates positively in insulin-stimulated 
glucose uptake.  These data indicate that PKC-ζ should be included in the group of Ser/Thr 
kinases that mediate insulin resistance induced by various metabolic and inflammatory or stress 
states (Fig. 10) (56).  The mechanism by which PKC-ζ remains chronically activated under these 
conditions requires further investigation.  Identifying the protein(s) responsible could lead to new 
therapeutic strategies that, while blocking negative feedback, preserve the positive role of PKC-ζ 
in insulin action. 
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Fig. 1. Effect of high glucose/insulin on glucose uptake and glucose transporters (GLUTs).  
Adipocytes were incubated at 37°C for 18 h in either DMEM containing 5.6 mM glucose 
(Control, open circles) or containing 20 mM glucose and 100 nM insulin (Resistant, closed 
circles). Cells were then extensively washed as described and incubated with the indicated 
concentrations of insulin for 30 min, followed by (A) assay of 2-deoxyglucose (2DG) uptake. 
Data shown are mean ± SE of 3 independent experiments (*p < 0.001, Resistant vs Control). (B) 
LDM and PM fractions were prepared from control and resistant cells and 30 µg protein resolved 
by SDS-PAGE and immunoblotted with anti-GLUT4 or (C) anti-GLUT1 antibody.  
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Immunoblots shown are from one of 3 independent experiments with similar results (see text for 
means ± SE). 
Fig. 2. Effect of high glucose/insulin on IRS-1 tyrosine phosphorylation and downstream 
signalling.  Adipocytes were incubated for 18 h as described in Fig.1. in Control (5.6 mM 
glucose) and Resistant (20 mM glucose and 100 nM insulin) (HG/HI)conditions, washed and 
restimulated in the presence and absence of 100 nM insulin. IRS-1 was immunoprecipitated from 
cell lysates (500 µg), resolved by SDS-PAGE and immunoblotted with (A) anti-IRS-1 and anti-
pY antibodies (B). Forty µg protein were resolved by SDS-PAGE and immunoblotted with anti-
Akt, anti-phospho-Akt (pSer473 and pThr308), anti-GSK-3 3α/β (GSK-3) and anti-
pSer9/pSer21 GSK-3 α/β (pGSK-3) antibodies.  (C) Total Akt was immunoprecipitated from 
cell lysates and in vitro kinase activity was determined using the peptide substrate Crosstide. 
Data shown are mean ± SE of 3 independent experiments (* p< 0.05, Resistant vs Control). (D) 
Akt2 was immunoprecipitated and immunoblotted with anti-Akt2 and anti-pSer473 Akt.  Insulin-
stimulated Akt2 Ser474 phosphorylation was reduced by 56±6.8% in insulin resistant cells (n=3, 
p<0.01) (E) Cells were incubated for 18 h in the presence of  5.6 mM glucose (control), 20 mM 
glucose without insulin (HG), 100 nM insulin without glucose supplemented with pryruvate (HI) 
or combined (HG/HI) as above.  Cell lysates were prepared and immunoblotted with anti-total 
and anti-pSer473 Akt.  The decrease in insulin-stimulated Akt phosphorylation was significant 
for HG/HI (64±9.4%) and HI (51±5.0%) (p<0.05 for both compared with control) (n=3) while 
there was no difference with HG (107±6.8% of control, n=3). 
Fig. 3. Effect of high glucose/insulin on Akt dephosphorylation.  Adipocytes were incubated 
for 18 h as described in Fig. 2, washed and restimulated in the presence and absence of insulin.  
(A)  Cell lysates (50 µg protein) from control (open circles) and resistant (closed circles) 
adipocytes were incubated with equal amounts of phosphorylated Akt immunoprecipitated from 
insulin-stimulated control adipocytes.  In vitro dephosphorylation was allowed to proceed as 
described at 30°C and at the times indicated aliquots removed, boiled in SDS sample buffer, 
resolved by SDS-PAGE and immunoblotted with anti-pSer473Akt and anti-total Akt antibodies.  
After correction for total Akt the relative intensities of pSer473 were plotted as % of maximum 
insulin-stimulated Akt phosphorylation prior to dephosphorylation.  (B and C)  After 
restimulation of control (open circles) and resistant (closed circles) adipocytes with 100 nM 
insulin for 15 min, 100 µM 2-DG and 5 µM rotenone were added to deplete cellular ATP and the 
incubation continued at 37°C (B) or 30°C (C) as described.  At the indicated times, cells were 
lysed and pSer473 Akt and total Akt immunoblotted and relative pSer473 Akt dephosphorylation 
determined as above.  *p<0.05, Control versus resistant. 
Fig. 4. Effect of high glucose/insulin on PKC translocation.  Adipocytes were incubated for 
18 h as described in Fig. 2. Cell lysates and cell membranes were prepared as described.  (A) 
Equal aliquots of protein of total cell lysates and cell membrane fractions were resolved by SDS-
PAGE and immunoblotted with antibodies against the various PKC isoforms indicated.  
Representative immunoblots are shown.  Graphs depict means ± SE (n=3) of membrane-
associated PKC isoforms in Control and Resistant (HG/HI) adipocytes.  **p<0.01, R versus C 
PKC-ζ.  Total cell lysate PKC protein content was not significantly different for any isoform. (B) 
PKC-ζ was immunoprecipitated from cell lysates and in vitro kinase activity determined as 
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described.  Data shown are mean ± SE of 6 independent experiments.  *p < 0.05 Control basal vs 
Control insulin, *** p < 0.005,  Resistant basal vs Control basal. 
Fig. 5 Effect of dominant-negative (DN) and constitutively active (CA) PKC-ζ on Akt 
phosphorylation.  Adipocytes were transiently transfected with wild-type myc-epitope tagged 
Akt (WT-Akt) along with (A) dominant-negative, PKC-ζ K281R (DN PKC-ζ) or (B) CA-PKC-ζ 
by electroporation. Cells transfected with empty vector (pcDNA3) served as control. After 
equilibration in DMEM for 1 h, the cells were washed and incubated for 18 h as described in Fig. 
2. After washing, the adipocytes were restimulated in the presence and absence of 100 nM 
insulin for 15 min, cell lysates were prepared and equal aliquots of protein separated by SDS-
PAGE and immunoblotted with anti-pSer473 and anti-PKCζ/λ antibodies. The transfected myc-
Akt is differentiated from endogenous Akt by its slower migration. (A) Overexpression of DN 
PKC-ζ prevented the high glucose/insulin-induced decrease in Akt Ser473 phosphorylation by 
90% (n=2) (see text for details).  (B) Insulin-stimulated Akt pSer473 was decreased compared 
with control (100%) by high glucose/insulin to 49± 11.2% (p<0.05), by CA-PK -ζ to 45± 10.5% 
(p<0.05) and by combined HG/HI and CA-PKC-ζ to 24±8.7% (P<0.01) (n=3).  (C) Transfected 
cells were incubated in a medium without glucose supplemented with pyruvate, cell lysates were 
prepared and immunoblotting performed as above.  CA-PKC-ζ decreased insulin-stimulated Akt 
pSer473 to 42±1.0% (p<0.01, n=3). 
Fig. 6 Inhibition of PKC-ζ reverses the high glucose/insulin induced defect in IRS-1 Tyr 
phosphorylation and downstream signaling. Adipocytes were incubated for 18 h as 
described in Fig. 2 with or without addition of (A) 10 µM myristoylated PKC-ζ specific PS 
inhibitor (PKC-ζ PS) or (B) 10 µM PKC-α/β PS inhibitor for the final 2 h (16-18 h). Cells were 
then washed and restimulated for 15 min in the presence and absence of 100 nM insulin. Cell 
lysates were immunoprecipitated with anti-IRS-1 antibodies and immunoblotted with anti-pY, 
anti-IRS-1 and anti-p85 as indicated.  Total cell lysates were immunoblotted with anti-pSer473, 
anti-pThr308, anti-Akt, anti-phospho-GSK3 and anti-GSK3 as indicated.  Immunoblots are 
representative of 3 separate experiments and the intensities of the phosphorylated proteins were 
corrected for total protein in each experiment determined by reprobing of stripped membranes.  
In the absence of PKC-ζ inhibitor the high glucose/high insulin (HG/HI) treatment decreased 
insulin-stimulated IRS-1 pY to 44.5±9.6% of control (p<0.01), IRS-1 association of p85 to 
46.9±0.4% of control (p<0.01), Akt pSer473 to 17.7±5. 4% and Akt pThr308 to 24.7±0.6% of 
control (p<0.005 for both) and pGSK3 to 49.1±2.7% of control (p<0.005) (n=3).  Two h of 
treatment with PKC-ζ inhibitor blocked these effects of HG/HI.  IRS-1 pY 94.0±7.8%, p85 
association 101.8±9.1%, Akt pSer473 92.5±4.4%, Akt  pThr308 84.1±9.4% and pGSK3 
100.5±10.7% (p=NS compared with control for all except Akt pThr 308 which was not 
completely reversed (p<0.05), n=3).  In contrast, in the presence of the PKC-α/β inhibitor  
insulin-stimulated Akt pSer473 remained decreased by ~ 60% in resistant cells.  Mean ± SE 
(n=3) insulin-stimulated Akt pSer473 corrected for total Akt (fold of control basal); Control 5.66 
± 1.68, Resistant 2.28 ± 0.71, Control + PKC α/β PS 5.44 ± 1.97, Resistant + PKC α/β PS 1.92 ± 
0.49. 
Fig. 7 Inhibition of PKC-ζ reverses the high glucose/insulin-induced defect in GLUT4 
translocation and insulin insensitivity of glucose uptake. Adipocytes were incubated and 
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treated with PKC-ζ PS inhibitor as described in Fig. 6. (A) PM and LDM were prepared and 
immunoblotted with anti-GLUT4 antibody as described in Fig. 1. Immunoblots are 
representative of 3 separate experiments.  The % (mean ±SE) of total GLUT4 in the PM after 
insulin stimulation were: control 66.0±7.6, HG/HI 40.4±5.3 (p< 0.01) and HG/HI+PKC-ζ PS 
78.5±3.8 (p=NS versus C, P<0.001 versus R).  The % (mean ± SE) decrease in LDM GLUT4 
after insulin stimulation were:  control 59.5±6.3, HG/HI 12.2 ± 4.2  (p<0.01) and HG/HI + PKC-
ζ PS 70.0 ± 3.2% (p=NS versus C, p< 0.001 versus R) (n=3) (B)  (Color online).  Adipocytes 
were transfected with a HA-GLUT4-GFP expression vector by electroporation and cells treated 
as in Fig.6. Confocal microscopic images were obtained and analyzed as described. Images are 
representative of 4 – 7 separate experiments. In 2 experiments in which all 8 conditions were 
performed together and 35-50 cells analyzed per condition the mean relative translocation was:  
Control basal 1.0; Control + Insulin 2.85; Control + PS inhibitor basal 1.25; Control + PS 
inhibitor + Insulin 3.0; Resistant basal 1.01; Resistant + Insulin 1.36; Resistant + PS inhibitor 
basal 1.51; Resistant + PS inhibitor + Insulin 2.93.  (C) Cells incubated in control medium (●,○), 
or high glucose/insulin containing medium (■,□) were treated with (broken lines, open symbols) 
or without (solid lines, filled symbols) PKC-ζ PS inhibitor for the final 2 h. Glucose uptake was 
performed as in Fig. 1. Results shown are values for glucose uptake normalized for basal uptake, 
designated as 0, and maximum uptake, designated as 100%, in each condition.  Values are the 
mean ± SE of 4-7 experiments performed in duplicate. *p<0.05 Resistant vs all other conditions 
(see text for details). (D) Maximum insulin-stimulated glucose uptake from experiments in C.  
Values shown are mean ± SE insulin-stimulated glucose uptake (pmol/5x106 cells/3 min); C 
(Control) 439±27.2, R (resistant) 240 ±8.2, C + PKC-ζ PS 455±71.8, R + PKC-ζ PS 383±34.0. 
*p<0.01 R versus C and C+PSI and p< 0.05 R versus R + PSI (n=4). 
Fig. 8 Transfection of IRS-1 S318A or Akt T34A reverses impaired IRS-1 Tyr and Akt Ser 
473 phosphorylation induced by either cotransfected CA-PKC-ζ or by treatment with high 
glucose/insulin. (A) Adipocytes were cotransfected with IRS-1 S318A (318), CA-PKC-ζ, (CA) 
and WT-Akt as indicated and cell lysates prepared.  Transfected WT myc-Akt was 
immunoprecipitated with anti-myc and immunoblotting performed as described. Immunoblots 
are representative of 3 separate experiments.  The values (mean ± SE) for insulin-stimulated 
IRS-1 pY corrected for total IRS-1 and myc-Akt  pSer473 corrected for total myc-Akt are shown 
in the graphs below.  Insulin-stimulated control (C/I) values were designated as 100%.  *p<0.05 
versus all other groups..  (B) Adipocytes were cotransfected with IRS-1 S318A (318) and WT 
myc-Akt and incubated in high glucose/insulin, washed and restimulated with insulin.  Cell 
lysates were prepared and immunoprecipitated with anti-myc antibodies and immunoblotted as 
described.  Immunoblots are representative of 3 separate experiments.  Values (mean ± SE) for 
insulin-stimulated IRS-1 pY and myc-Akt pSer473 and pThr308 are shown in the graphs below. 
** p<0.01 and *p<0.05, versus all other groups. (C) Adipocytes were cotransfected with WT 
myc-Akt or mutant HA-Akt T34A and either pcDNA 3.0 (empty vector) or CA-PKCζ (CA) and 
cell lysates prepared, immunoprecipitated with anti-myc or anti-HA and immunoblotted as 
above. Immunoblots are representative of 3 separate experiments.  Values (means ± SE) for 
insulin-stimulated myc-Akt pSer473 and pThr 308 and HA-Akt T34A pSer473 and pThr 308 are 
shown in the graphs below.  **p<0.01 versus all other groups. (D) Adipocytes were transfected 
with WT myc-Akt or HA-Akt T34A and incubated in control or HG/HI medium as in Fig. 2.  
Immunoblots are representative of 3 separate experiments.  Values (mean ± SE) for insulin-
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stimulated myc-Akt pSer 473 and pThr 308 and HA-Akt T34A pSer 473 and pThr 308 are 
shown in the graphs below.  **p<0.01 versus all other groups.  (E) Adipocytes were transfected 
as indicated and incubated in control or HG/HI medium as in D.  Cell lysates were prepared and 
immunoprecipitation and immunoblotting performed as above. Immunoblots are representative 
of 3 separate experiments.  Values (mean ± SE) for insulin-stimulated myc-Akt pSer 473 and 
pThr 308 and HA-Akt T34A pSer 473 and pThr 308 are shown in the graphs below **p<0.01 
versus all other groups. 
Fig. 9  In vivo 48h hyperglycemia/hyperinsulinemia causes insulin resistance associated 
with augmented IRS-1 Ser318,Akt Thr34 and PKC-ζ pThr 410 phosphorylation.  Rats were 
infused for 48h with glucose to maintain hyperglycemia 20-22 mM, (R=resistant) (n=4) or saline  
(C=control) (n=4).  Adipocytes were isolated, washed and stimulated or not with 100 nM insulin 
(I) as described in Methods.  Lysates were prepared, equal amounts of protein separated by SDS-
PAGE and immunoblotted with A) antibodies to total Akt, Akt pSer473, Akt pThr34; B) total 
IRS-1, phosphotyrosine (pY), IRS-1 pSer318 and IRS-1 pSer307; and C) total PKC-ζ and PKC-
ζ pThr410.  Representative immunoblots are shown and the graphs below depict densitometric 
values (mean±SE) of phosphorylated proteins corrected for total Akt (A), total  IRS-1 (B) total 
PKC-ζ (C) and expressed relative to control basal (C/B). A)  Akt pSer 473, **p<0.01, C/I vs all 
other groups; Akt pThr34 *p<0.05, R vs C.  B)  pY, ** p<0.01 C/I vs all other groups; IRS-1 
pSer318, ** p<0.01 R vs C.  C)  PKC-ζ pThr 410, *p<0.05 R vs C.  
Fig. 10  (Color Online) PKC-ζ induces insulin resistance by dual targeting of IRS-1 and 
Akt.  Insulin resistance is associated with a number of pathophysiological factors including 
elevated circulating levels of metabolites, AA (amino acids), glucose, FFA (free fatty acids); pro-
inflammatory cytokines, e.g. TNF-α; oxidative stress (O2.-) and chronic hyperinsulinemia.  These 
in turn, activate various unique and interacting signaling pathways that commonly result in 
phosphorylation of IRS-1 to inhibit insulin action.  Hyperinsulinemia combined with 
hyperglycemia activates several of these downstream pathways, e.g .JNK, which may exert rapid 
and short term negative feedback.  PKC-ζ however, appears to remain chronically activated and 
sustains insulin resistance by phosphorylation of two targets, IRS-1 Ser 318 and Akt Thr 34.  The 
role of PKC-ζ and phosphorylation of these targets in maintaining decreased insulin sensitivity 
in human subjects requires further study. 
Antibodies used.  RRID numbers are from http://antibodyregistry.org. 
Antibody Source RRID 
Akt Cell Signaling Technology AB_329827 
Phospho-Akt (Ser473) Cell Signaling Technology AB_329825 
Phospho-Akt (Thr308) Cell Signaling Technology AB_329828 
AKT1 (phosphoT34) Abcam AB_2558095 
Anti-Human Akt2 (F-7) Santa Cruz Biotechnology AB_626659 
Phospho-PCKζ/λ (Thr410/403) Cell Signaling Technology AB_2168217 
PKC zeta (C-20 Santa Cruz Biotechnology AB_2300359 
PCK beta (C-16 Santa Cruz Biotechnology AB_2168968 
PKC delta (C-17) Santa Cruz Biotechnology AB_632228 
PKC epsilon (C-15) Santa Cruz Biotechnology AB_2237729 
IRS-1 Cell Signaling Technology AB_330333 
Phospho Ser307-IRS-1 Millipore AB_11213228 
Anti-IRS1 Agarose Conjugated Millipore AB_310783 
Phospho Ser318-IRS-1 (D51C3) Cell Signaling Technology AB_10695244 
p-Tyr (PY99) Santa Cruz Biotechnology AB_628123 
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23 
Glucose Transporter GLUT1 Novus AB_790014 
Glucose Transporter GLUT4 Millipore AB_211989 
Anti-P13 Kinase, p85 Polyclonal Millipore AB_310141 
Anti-GSK-3 alpha/beta Millipore AB_11205766 
Phospho-GSK-3 alpha/beta (S21/S9) R and D Systems AB_354880 
c-Myc (9E10) antibody Santa Cruz Biotechnology AB_627268 
HA.11 Monoclonal Antibody Covance Research Products Inc AB_10063630 
Phospho Ser636/639 IRS-1 Millipore AB_1587211 
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